EUVIMEDOpdag EUVIMED
Multizentrische StudieRandomisierte kontrollierte StudieOpen access

Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial

Catherine G Ireland, Danielle S Burstein, Sharlene M Day iD, Anna Axelsson Raja iD, Mark W Russell iD, Kenneth G Zahka, Alexandre Pereira, Charles E Canter iD, Richard G Bach, Matthew T Wheeler iD, Joseph W Rossano iD, Anjali T Owens iD and 12 more

Circulation: Heart Failure · 2024-08 · 17 (8)

DOI: 10.1161/circheartfailure.124.011663 ↗

At a glance

Multizentrische Studie in Circulation: Heart Failure, 2024-08. Written by Catherine G Ireland and 23 co-authors. Institution: Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.G.I., E.J.O., B.C., C.Y.H.). Major MEDLINE topics: Cardiomyopathy, Hypertrophic, Exercise Test, Exercise Tolerance, Quality of Life. Cited 8 times so far (Crossref); 33 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being. METHODS: VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort. RESULTS: Two hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8; P =0.005). Both cohorts demonstrated mildly reduced functional status (mean percent predicted peak oxygen uptake 73±16 versus 78±12 mL/kg per minute; P =0.18). Percent predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL. Valsartan improved physical HRQOL in early stage HCM (adjusted mean change in pediatric quality of life score +4.1 versus placebo; P =0.01) but did not significantly impact CPET performance. CONCLUSIONS: Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01912534.

Subjects

MeSH terms (MEDLINE)

Cardiomyopathy, HypertrophicExercise TestExercise ToleranceQuality of LifeValsartanAdolescentAdultChildFemaleHumansMaleYoung AdultAngiotensin II Type 1 Receptor BlockersTreatment Outcome

Author keywords

cardiomyopathy, hypertrophicexercise testfunctional statuspsychological well-beingquality of life

Substances

Angiotensin II Type 1 Receptor BlockersValsartan

Authors and institutions

  • Brigham and Women's Hospital, Harvard Medical School, Boston, MA (C.G.I., E.J.O., B.C., C.Y.H.).
  • University of Vermont Larner School of Medicine, Burlington (D.S.B.).
  • University of Pennsylvania Perelman School of Medicine, Philadelphia (S.M.D., A.T.O.).
  • Copenhagen University Hospital, Rigshospitalet, Denmark (A.A.R., H.B.).
  • University of Michigan, Ann Arbor (M.W.R.).
  • Cleveland Clinic Foundation, OH (K.G.Z.).

ORCID profiles: Sharlene M Day, Anna Axelsson Raja, Mark W Russell, Charles E Canter, Matthew T Wheeler, Joseph W Rossano, Anjali T Owens, Henning Bundgaard, Luisa Mestroni, Matthew R G Taylor, Amit R Patel, Jonathan H Soslow, Jason R Becker, Ilya Giverts, E John Orav, Brian Claggett, Kimberly Y Lin

Funding

  • NHLBI NIH HHS

Cite

APA

Ireland, C. G., Burstein, D. S., Day, S. M., Axelsson Raja, A., Russell, M. W., Zahka, K. G., Pereira, A., Canter, C. E., Bach, R. G., Wheeler, M. T., Rossano, J. W., Owens, A. T., Bundgaard, H., Mestroni, L., Taylor, M. R. G., Patel, A. R., Wilmot, I., Soslow, J. H., Becker, J. R., …, & Ho, C. Y. (2024). Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial. Circulation: Heart Failure, 17(8). https://doi.org/10.1161/circheartfailure.124.011663

Vancouver

Ireland CG, Burstein DS, Day SM, Axelsson Raja A, Russell MW, Zahka KG, et al. Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial. Circulation: Heart Failure. 2024;17(8). doi:10.1161/circheartfailure.124.011663

BibTeX
@article{Ireland2024,
  author = {Ireland, Catherine G and Burstein, Danielle S and Day, Sharlene M and Axelsson Raja, Anna and Russell, Mark W and Zahka, Kenneth G and Pereira, Alexandre and Canter, Charles E and Bach, Richard G and Wheeler, Matthew T and Rossano, Joseph W and Owens, Anjali T and Bundgaard, Henning and Mestroni, Luisa and Taylor, Matthew R G and Patel, Amit R and Wilmot, Ivan and Soslow, Jonathan H and Becker, Jason R and Giverts, Ilya and Orav, E John and Claggett, Brian and Lin, Kimberly Y and Ho, Carolyn Y},
  title = {Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial},
  journal = {Circulation: Heart Failure},
  year = {2024},
  volume = {17},
  number = {8},
  doi = {10.1161/circheartfailure.124.011663}
}
Start for free →